BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss

Reuters02-19 22:11
BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss

** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O down 6% at $462.10 premarket

** Co reports Q4 loss of $2.57 per share vs analysts' estimated loss of 40 cents per share - LSEG data

** MDGL posts Q4 net revenue of $321.1 million vs estimates of $312.5 million

** Truist Securities says "the 12% Q4 and Q3 revenue growth reflecting consistent progress should aid in providing investor confidence that the company can continue to execute on Rezdiffra"

** As of December 31, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $988.6 million, compared with $931.3 million a year ago

** In 2025, MDGL was up 88.7%

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment